Rhythm Pharmaceuticals (RYTM) Q4 2025 earnings review
Steady BBS Growth Sets Stage for Pivotal HO Launch, but Operating Costs Surge
Rhythm Pharmaceuticals delivered a strong finish to FY25 with Q4 global IMCIVREE sales accelerating 37% YoY to $57.3M, driven by steady Bardet-Biedl syndrome (BBS) uptake and international expansion. However, the underlying narrative is entirely focused on the upcoming March 20, 2026 PDUFA date for Acquired Hypothalamic Obesity (HO). To support this transformative launch, management is spending aggressively. Q4 SG&A expenses surged 51% YoY to $57.5M, completely swallowing the revenue gains and keeping the net loss stable at $48.8M. While the $388.9M cash position provides a secure 24-month runway, the company's FY26 guidance signals a massive jump in operating expenses, meaning near-term profitability remains out of reach. The investment thesis hinges entirely on a flawless execution of the HO commercial launch.
🐂 Bull Case
The upcoming PDUFA date (March 20, 2026) for Acquired HO is a massive catalyst. The company has spent FY25 scaling its commercial infrastructure and identifying over 2,000 potential patients, positioning it for rapid uptake post-approval.
The core BBS business is accelerating, with consecutive QoQ growth demonstrating successful market penetration, strong prescriber retention, and new reimbursement victories in Canada.
🐻 Bear Case
Despite a $15.5M YoY increase in Q4 revenue, Net Loss actually worsened by $4.2M. SG&A and R&D costs are climbing much faster than sales, pushing any timeline for profitability further into the future.
The Prader-Willi Syndrome (PWS) indication remains a highly complex, historically risky target. Management has previously handicapped the Phase 2 trial odds at '50-50,' making the upcoming H1 2026 readout a potential volatility event.
⚖️ Verdict: 🟢
Bullish. The core BBS business is proving management's commercial competence, and the balance sheet is adequately capitalized to fund the pivotal Acquired HO launch. The massive expense ramp is concerning but justifiable given the size of the HO market opportunity.
Key Themes
Acquired HO PDUFA and Commercial Readiness
The dominant catalyst is the March 20, 2026, PDUFA date for setmelanotide in Acquired Hypothalamic Obesity. This indication dramatically expands the addressable market (estimated 5,000-10,000 US patients). Management has built out a specialized field force targeting community endocrinologists, signaling confidence in an immediate, aggressive commercial rollout.
Surging Operating Expenses Contradict Revenue Gains
A specific contradiction to the positive commercial momentum is the complete lack of operating leverage. While Q4 revenue grew an impressive 37% YoY to $57.3M, Q4 SG&A expenses surged 51% YoY to $57.5M. This accelerating expense profile is expected to worsen, with FY26 Non-GAAP OpEx guided to surge by roughly $105M YoY at the midpoint.
International Expansion Gaining Traction
Ex-US revenue is accelerating, hitting $18.3M in Q4 (32% of total product revenue), a sequential increase of 40%. This was supported by new Product Listing Agreements across six Canadian provinces and stabilization following a one-time pricing adjustment in France in Q3.
Macro Reimbursement Complexities Delaying Ex-US Ramp
While international revenue grew, the company remains highly vulnerable to sovereign macro pricing negotiations. As seen with the retroactive $3.2M charge in Q3 related to the French CEPS agreement, navigating fragmented, country-by-country European healthcare systems causes significant revenue lumpiness and delays widespread access.
Next-Generation Technology Lifecycle Management
Rhythm is actively protecting its franchise via technological innovation in the MC4R pathway. The company completed a positive end-of-Phase-2 FDA meeting for bivamelagon (an oral formulation) and is on track to initiate a Phase 3 trial in Acquired HO by year-end 2026. Concurrently, enrollment continues for RM-718 (a weekly injectable), moving the portfolio away from daily injections.
Prader-Willi Syndrome (PWS) Clinical Cliff
The company is awaiting six-month results from its exploratory Phase 2 trial of setmelanotide in PWS in H1 2026. Given management's prior historical commentary framing this as a '50-50' probability due to the behavioral complexities of the disease, this remains a binary risk event that could heavily impact sentiment.
Other KPIs
Accelerating. Total revenue grew approximately 50% YoY from $130.1 million in FY24, showcasing strong underlying demand for IMCIVREE in the foundational BBS indication despite inventory volatility earlier in the year.
Stable. The balance declined slightly from Q3 2025 ($416.1M) due to operational burn but remains significantly higher than the $320.6M reported at the end of FY24. Management explicitly confirmed this provides at least 24 months of runway.
Decelerating. Down from $238.0 million in FY24, primarily due to the non-recurrence of in-process R&D costs associated with the acquisition of the bivamelagon compound in the prior year. However, base clinical trial costs remain elevated as multiple late-stage trials progress.
Guidance
Accelerating dramatically. The $400 million midpoint represents a roughly 35% jump from FY25's $295.5 million. This aggressive spending profile is fueled by the Acquired HO commercial buildout and concurrent progression of multiple Phase 3 trials (bivamelagon, EMANATE).
Accelerating. The midpoint of $205 million implies steady commercial expansion to support the US Acquired HO launch and continued international rollout, maintaining the heavy cost structure established in Q4 2025.
Accelerating. Moving from $167.3 million in FY25 to a midpoint of $195 million in FY26, signaling intense capital commitment to pipeline progression, specifically the initiation of the pivotal Phase 3 bivamelagon trial.
Key Questions
Path to Operating Leverage
With FY26 Non-GAAP operating expenses guided to $400 million at the midpoint, at what annualized revenue run-rate for the Acquired HO franchise do you expect the company to begin demonstrating meaningful operating leverage?
PWS Trial Risk Mitigation
Given previous commentary framing the Prader-Willi Syndrome (PWS) indication as a '50-50' clinical risk, how is the company mitigating downside risk, and what specific efficacy floor is required in the H1 2026 data to justify advancing to Phase 3?
Ex-US Revenue Composition
International revenue jumped 40% sequentially in Q4 to $18.3 million. How much of this was driven by structural reimbursement agreements (like Canada) versus inherently lumpy named-patient or early access programs?
Bivamelagon Transition Strategy
As the oral bivamelagon program advances toward a Phase 3 trial in Acquired HO, how does management view the long-term cannibalization risk versus market expansion benefit against the injectable setmelanotide franchise?